Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-14T16:30:16.811Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacotherapy for anxiety disorders: drugs available

Published online by Cambridge University Press:  02 January 2018

P. J. Cowen
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The human search for tranquillity has embraced the use of numerous substances of which alcohol is probably the most widely used. Alcohol acts in part by facilitating neurotransmission at γ-aminobutyric acid (GABA) synapses and until recently the pharmacological treatment of anxiety was based principally on drugs that produce similar actions on this neurotransmitter and its receptor complex (Cowen & Nutt, 1982) (Box 1).

Type
Research Article
Information
Advances in Psychiatric Treatment , Volume 3 , Issue 2 , March 1997 , pp. 66 - 71
Copyright
Copyright © The Royal College of Psychiatrists 1997 

References

Appleby, L. (1994) Panic and suicidal behaviour. British Journal of Psychiatry, 164, 719–721.Google ScholarPubMed
Bezchlibnyk-Butler, K. Z. & Jeffries, J. J. (1995) Handbook of Psychotropic Drugs, pp. 67–71. Seattle, WA: Hogrefe & Huber.Google Scholar
Black, D. W., Wesner, R., Bowers, W. et al (1993) A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44–50.Google Scholar
Clark, D. M., Salkovskis, P. M., Hackmann, A. et al (1994) A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. British Journal of Psychiatry, 164, 759–769.CrossRefGoogle ScholarPubMed
Cohn, J. B. & Wilcox, C. S. (1992) Paroxetine in major depression: a double-blind trial with imipramine and placebo. Journal of Clinical Psychiatry, 53 (suppl. 2), 52–56.Google Scholar
Cowen, P. J. & Nutt, D. J. (1982) Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism? Lancet, ii, 360–362.Google Scholar
Den Boer, J. A. & Westenberg, H. G. M. (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder, a double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59–74.Google Scholar
Hayes, P. E. & Schulz, S. C. (1987) Beta-blockers in anxiety disorders. Journal of Affective Disorders, 13, 119–130.Google Scholar
Kahn, R. J., McNair, D. M., Lipman, R. S. et al (1986) Imipramine and chlordiazepoxide in depressive and anxiety disorders. Archives of General Psychiatry, 43, 79–85.CrossRefGoogle ScholarPubMed
Kelly, D., Guirguis, W, Frommer, E. et al (1970) Treatment of phobic states with antidepressants. A retrospective study of 246 patients. British Journal of Psychiatry, 116, 387–398.Google Scholar
Lader, M. (1991) Can buspirone induce rebound, dependence or abuse? British Journal of Psychiatry, 159 (suppl. 12), 45–51.Google Scholar
Liebowitz, M. R., Schneier, F., Campeas, R. et al (1992) Phenelzine versus atenolol in social phobia: a placebo-controlled comparison. Archives of General Psychiatry, 49, 290–300.Google Scholar
Lydiard, R. B. & Ballenger, J. C. (1987) Antidepressants in panic disorder and agoraphobia. Journal of Affective Disorders, 13, 153–168.Google Scholar
Marshall, R. D., Schneier, F. R., Fallon, B. A. et al (1994) Medication therapy for social phobia. Journal of Clinical Psychiatry, 55 (suppl. 6), 33–37.Google ScholarPubMed
Mavissakalian, M. R. & Perel, J. M. (1995) Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. American Journal of Psychiatry, 152, 673–682.Google ScholarPubMed
Modigh, K., Westberg, P. & Eriksson, E. (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. Journal of Clinical Psychopharmacology, 12, 251–261.Google Scholar
Oehrberg, S., Cristiansen, P. E., Behnke, K. et al (1995) Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374–379.CrossRefGoogle ScholarPubMed
Ortiz, A., Pohl, R. & Gershon, S. (1987) Azaspirodecanediones in generalised anxiety disorder: buspirone. Journal of Affective Disorders, 13, 131–143.Google Scholar
Power, A. C. & Cowen, P. J. (1992) Fluoxetine and suicidal behaviour. Some clinical and theoretical aspects of a controversy. British Journal of Psychiatry, 161, 735–741.CrossRefGoogle ScholarPubMed
Priest, R. G. (1990) Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants. Acta Psychiatrica Scandinavica, 360, 39–41.Google Scholar
Rickeis, K., Schweizer, E., Weiss, S. et al (1993a) Maintenance drug treatment for panic disorder. 2: Short and long term outcome after drug taper. Archives of General Psychiatry, 50, 61–68.Google Scholar
Rickeis, K., Downing, R., Schweizer, E. et al (1993b) Antidepressants for the treatment of generalised anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Archives of General Psychiatry, 50, 884–895.Google Scholar
Schweizer, E., Rickeis, K., Weiss, S. et al (1993) Maintenance drug treatment of panic disorder. 1: Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Archives of General Psychiatry, 50, 51–60.CrossRefGoogle ScholarPubMed
Sheehan, D. V., Raj, A. B., Harnett-Sheehan, K. et al (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatrica Scandinavica, 88, 1–11.Google Scholar
Soloff, P. H., George, A., Nathan, S. et al (1986) Progress in pharmacotherapy of borderline disorders. Archives of General Psychiatry, 43, 691–697.Google Scholar
Taylor, D. & Lader, M. (1996) Cytochromes and psychotropic drug interactions. British Journal of Psychiatry, 168, 529–532.Google Scholar
van Vliet, I. M., Den Boer, J. A. & Westenberg, H. G. M. (1994) Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology, 115, 128–134.Google Scholar
Versiani, M., Nardi, A. E. & Mundim, F. D. (1992) Pharmacology of social phobia. A controlled study of moclobemide and phenelzine. British Journal of Psychiatry, 161, 353–360.CrossRefGoogle Scholar
Yocca, F. D. (1990) Neurochemistry and neurophysiology of buspirone and gepirone: interactions of pre-synaptic and post-synaptic 5-HT1A receptors. Journal of Clinical Psychopharmacology, 10 (suppl. 3), 6S–12S.CrossRefGoogle Scholar
Young, A. H. & Cowen, P. J. (1995) Antidepressant drugs. In Side-Effects of Drugs Annual 18 (eds Aronson, J. K. & van Boxtel, C. J.) pp. 14–24. Amsterdam: Elsevier.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.